World OTC Pharmaceuticals Market Forecast 2015-2025 : Prospects For Leading Companies

OTC医薬品(一般用医薬品)の世界市場

◆タイトル:World OTC Pharmaceuticals Market Forecast 2015-2025 : Prospects For Leading Companies
◆商品コード:VGAIN4121911
◆調査・発行会社:visiongain
◆発行日:2014年12月
◆ページ数:245
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserGBP1,799 ⇒換算¥266,252見積依頼/購入/質問フォーム
Five UsersGBP2,999 ⇒換算¥443,852見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥739,852見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、OTC医薬品(一般用医薬品)の世界市場について調査・分析し、レポートサマリー、市場概要、世界市場分析(市場規模、市場予測、促進要因、抑制要因)、セグメント別分析、主要地域別分析、市場環境分析、専門家の見解、主要企業分析、結論などの情報をお届けいたします。

World OTC pharmaceuticals – your guide to technologies, trends and revenues
Where is the world OTC pharmaceutical market heading? Visiongain’s new report gives you revenue, trends, opportunities, helping you stay ahead.

Our 245-page report provides 154 tables, charts, and graphs. Discover the growing trends of this industry. In particular, our new study lets you assess forecasted sales of the overall world market and at the national and leading manufacturer level. You will see financial results, drivers and restraints, and revenue predictions.

Besides revenue forecasts to 2025, this report provides you with market shares, business outlooks, qualitative analyses (including SWOT and Porter’s Fiver Forces Analysis), company profiles and commercial developments. Also, read the full transcripts of 2 exclusive interviews informing you about prospects for OTC switching and regulatory changes from:
• Professor Joshua P. Cohen, PhD, Tufts Center for the Study of Drug Development, Boston, Massachusetts, USA
• Mr David Spangler, Senior Vice President, US Consumer Health Products Association, Washington DC, USA

Many opportunities exist in the growing OTC pharmaceutical market. Our new study shows you the most promising parts of the market, helping you stay ahead.

Discover sales predictions for the overall OTC pharmaceuticals market and the individual national markets
Our analyses show you individual revenue forecasts to 2025 for 14 individual national markets:
• US
• Japan
• Germany
• France
• UK
• Italy
• Spain
• China
• Brazil
• Russia
• India
• Indonesia
• Mexico
• Turkey
• Rest of world

Additionally, our report provides revenues for the leading OTC manufacturers operating in leading national markets.

This will give you insight into the current market positions of the leading OTC pharmaceutical national markets and how their market positions are set to change over the forecast period.

See revenue forecasts for OTC pharmaceuticals submarkets
Along with prediction of overall world market value to 2025, our report shows you revenue forecasts for 7 leading submarkets at world level:
• Cough, Cold and Allergy
• Analgesics
• Gastrointestinals
• Dermatologicals
• Eye care
• Smoking Cessation Aids
• Other Products

Also our study discusses what OTC products are available in each submarket. The analysis helps you identify potential and find ways for your business to develop.

See revenue forecasts for products
How will leading OTC pharmaceuticals perform to 2025 at world level? Our study forecasts sales of leading OTC pharmaceutical drugs, including these brands:
• Panadol
• Voltaren
• Aspirin
• Claritin
• Tylenol
• Advil

Discover how high revenues can go. You will see what is happening, understanding trends, challenges and opportunities.

Leading companies and potential for market growth
Overall world revenue for OTC drugs will reach $92.9bn in 2015, our work forecasts. We predict revenue growth from 2015 to 2025. Our work shows you business activity currently occurring within the OTC pharmaceuticals industry. See profiles of the following leading companies:
• Bayer
• Merck
• GSK
• Novartis
• Johnson & Johnson
• Perrigo
• Pfizer
• Procter & Gamble
• Reckitt Benckiser
• Sanofi
• Boehringer Ingelheim

【レポートの目次】

1. Report Overview
1.1 The OTC Pharmaceuticals Market Overview
1.2 OTC Pharmaceuticals Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. Introduction to OTC Pharmaceuticals
2.1 What are OTC Pharmaceuticals?
2.2 Classification of OTC Pharmaceuticals
2.3 What are the Requirements for an OTC Pharmaceutical Drug?
2.4 OTC Switching
2.4.1 How is a Drug Switched from Prescription to OTC?
2.5 Manufacturing and Distribution of OTC Pharmaceuticals
2.6 Regulation of OTC Pharmaceuticals
2.6.1 Regulation of OTC Pharmaceuticals in the US
2.6.2 Regulation of OTC Pharmaceuticals in Japan: Deregulating the Sales of OTCs
2.6.3 Regulation of OTC Pharmaceuticals in Europe
2.6.4 Regulation of OTC Pharmaceuticals in China
2.6.5 Regulation of OTC Pharmaceuticals in Others Countries
2.7 OTC Pharmaceuticals: Market Segmentation
2.7.1 Analgesics
2.7.1.1 Internal Analgesics
2.7.1.2 External Analgesics
2.7.2 Cough, Cold and Allergy Products
2.7.2.1 Cough and Cold Remedies
2.7.2.2 Anti-Allergy Products
2.7.3 Dermatological Products
2.7.3.1 Minor Cuts and Wounds
2.7.3.2 Acne
2.7.3.3 Rashes, Itchy Skin, and Dermatitis/Eczema
2.7.3.4 Cold Sores
2.7.3.5 Warts
2.7.3.6 Fungal Skin Infections
2.7.3.7 Haemorrhoids
2.7.3.8 Other Dermatological Products
2.7.4 Gastrointestinal Products
2.7.4.1 Indigestion and Heartburn
2.7.4.2 Anti-Diarrhoea OTC Pharmaceuticals
2.7.4.3 Laxatives
2.7.4.4 Anti-Emetic OTC Pharmaceuticals
2.7.4.5 Anti-Obesity OTC Pharmaceuticals
2.7.5 Eye Care
2.7.5.1 Dry Eye Syndrome
2.7.5.2 Bacterial Conjunctivitis
2.7.5.3 Ocular Allergy and Allergic Conjunctivitis
2.7.5.4 Treatment of Ocular Allergy/ Allergic Conjunctivitis
2.7.6 Smoking Cessation Aids
2.7.7 Vitamins, Minerals and Supplements

3. The World OTC Pharma Market 2015-2025
3.1 The World OTC Pharma Market in 2013 and 2014
3.1.1 OTC Pharma Market Segmentation in 2013 and 2014
3.1.2 Leading OTC Pharma Brands
3.1.3 Leading Companies in the OTC Market
3.2 The World OTC Pharma Market: Sales Forecast, 2015-2025
3.2.1 The World OTC Pharma Market, 2015-2025: Drivers and Restraints
3.3 OTC Pharma Market Segments: Sales Forecasts, 2015-2025
3.3.1 CAGRs by OTC Segment, 2015-2025
3.3.2 Changing Market Shares by OTC Segment, 2015-2025
3.3.3 Cough, Cold and Allergy OTC Market: Sales Forecast 2015-2025
3.3.4 Analgesics OTC Market: Sales Forecast 2015-2025
3.3.5 Gastrointestinal OTC Market: Sales Forecast 2015-2025
3.3.6 Dermatological OTC Market: Sales Forecast 2015-2025
3.3.7 Eye Care OTC Market: Sales Forecast 2015-2025
3.3.8 Smoking Cessation OTC Market: Sales Forecast 2015-2025
3.3.9 Other OTC Market: Sales Forecast 2015-2025

4. The Leading National Markets 2015-2025
4.1 Regional Breakdown of the World OTC Pharma Market in 2013 and 2014
4.2 The World OTC Pharmaceutical Market: Regional Forecast, 2015-2025
4.3 Changing Market Shares of Leading National Markets: Emerging Dominance of China
4.4 The US OTC Pharmaceutical Market Sales Forecast, 2015-2025
4.4.1 The US OTC Pharma Market: Financial Incentives to Using OTC Drugs
4.4.2 The US OTC Pharma Market: Leading Companies
4.5 The Japanese OTC Pharmaceutical Market Sales Forecast, 2015-2025
4.5.1 The Japanese OTC Pharma Market: Deregulation could Stimulate Growth
4.5.2 The Japanese OTC Pharma Market: Leading Companies
4.6 The EU5 OTC Pharma Market in 2013 and 2014
4.6.1 Changing Market Shares of the EU5 OTC Pharmaceuticals Market
4.6.2 The EU5 OTC Market Sales Forecast, 2015-2025
4.6.3 The EU5 OTC Pharma Market: Leading Companies
4.6.4 The German OTC Pharmaceutical Market Sales Forecast, 2015-2025
4.6.5 The UK OTC Pharmaceutical Market Sales Forecast, 2015-2025
4.6.5.1 The UK’s Liberal OTC Regulations
4.6.6 The French OTC Pharmaceutical Market Sales Forecast, 2015-2025
4.6.6.1 OTC Drugs: A French Monopoly System
4.6.7 The Italian OTC Pharmaceutical Market Sales Forecast, 2015-2025
4.6.8 The Spanish OTC Pharmaceutical Market Sales Forecast, 2015-2025
4.7 The Chinese OTC Pharmaceutical Market Sales Forecast, 2015-2025
4.7.1 The Chinese OTC Pharma Market: Leading Companies
4.7.2 The Role of Traditional Chinese Medicines (TCM) in the Chinese OTC Market
4.8 The Brazilian OTC Pharmaceutical Market Sales Forecast, 2015-2025
4.8.1 The Brazilian OTC Pharma Market: Leading Companies
4.8.2 The Brazilian OTC Pharma Market: An Overview
4.9 The Russian OTC Pharmaceutical Market Sales Forecast, 2015-2025
4.9.1 The Russian OTC Pharma Market: Leading Companies
4.9.2 The Russian OTC Pharma Market: Overview
4.10 The Indian OTC Pharmaceutical Market Sales Forecast, 2015-2025
4.10.1 The Indian OTC Pharma Market: Leading Companies
4.10.2 The Indian OTC Pharma Market: An Overview
4.11 The Mexican OTC Pharmaceutical Market Sales Forecast, 2015-2025
4.11.1 Mexican OTC Manufacturers Reach New Heights
4.12 The Turkish OTC Pharmaceutical Market Sales Forecast, 2015-2025
4.13 The Indonesian OTC Pharmaceutical Market Sales Forecast, 2015-2025
4.14 The Rest of the World OTC Pharmaceutical Market Sales Forecast, 2015-2025

5. Leading Companies in the OTC Pharma Market 2015-2025
5.1 Leading OTC Pharmaceutical Manufacturers, 2013
5.1.1 Projected Leading OTC Pharmaceutical Manufacturers, 2015
5.2 GSK (Joint Venture with Novartis)
5.2.1 GSK Consumer Healthcare Unit: Historical Activity
5.2.2 GSK and Novartis Combine their OTC Businesses
5.2.3 GSK/Novartis: Additional Transactions
5.2.4 GSK Consumer Healthcare: OTC Sales Forecast, 2015-2025
5.2.5 Panadol
5.2.5.1 Panadol: Sales Forecast, 2015-205
5.2.6 Alli: A Beleaguered Brand
5.2.6.1 GSK Smoking Cessation Products
5.3 Novartis (OTC Joint Venture with GSK)
5.3.1 Novartis: Transformational Year
5.3.2 Voltaren
5.3.2.1 Voltaren: Sales Forecast 2015-2025
5.4 Bayer
5.4.1 Acquisition of Merck’s Consumer Care Business, 2014
5.4.2 Bayer: OTC Sales Forecast, 2015-2025
5.4.3 Bayer Aspirin
5.4.4 Bayer Aspirin: Sales Forecast 2015-2025
5.5 Merck (Acquired by Bayer)
5.5.1 Claritin OTC (Loratadine)
5.6 Johnson and Johnson
5.6.1 FDA Governance of McNeil Manufacturing Activity
5.6.2 Expansion in Developing Markets through Acquisitions
5.6.3 Johnson & Johnson: OTC Sales Forecast, 2015-2025
5.6.4 Tylenol
5.6.5 Tylenol: Sales Forecast, 2015-2025
5.6.6 Nicorette
5.7 Perrigo
5.7.1 Perrigo: OTC Sales Forecast, 2015-2025
5.7.2 Perrigo: Growth by Acquisition
5.7.3 Perrigo Bids for Omega Pharma
5.7.4 Perrigo’s Product Launches in FY 2013
5.7.5 Perrigo Benefits from Challenges Faced by J&J
5.8 Pfizer
5.8.1 Pfizer: OTC Sales Forecast, 2015-2025
5.8.2 Pfizer Acquires Rights to AstraZeneca’s OTC Nexium
5.8.3 Pfizer: Bulking up their OTC Product Portfolio
5.8.4 Advil
5.8.5 Advil: Sales Forecast, 2015-2025
5.9 Procter & Gamble
5.9.1 PGT Healthcare- Procter& Gamble’s Joint Venture with Teva
5.9.2 Prilosec OTC
5.9.3 Major Plans for Divestment Including OTC Products
5.10 Reckitt Benckiser
5.10.1 Reckitt Benckiser: OTC Sales Forecast, 2015-2025
5.10.2 Internal Growth by “Power” Brand Extensions: Mucinex
5.10.3 Expanding Presence in Emerging Markets through Acquisition
5.11 Sanofi
5.11.1 Sanofi: Acquisition of OTC Products from J&J
5.11.2 Sanofi: Launch of Nasacort
5.11.3 Sanofi: OTC Sales Forecast, 2015-2025
5.12 Boehringer Ingelheim
5.12.1 Boehringer Ingelheim: OTC Sales Forecast, 2015-2025

6. OTC Switching and Potential Future OTC Drugs
6.1 OTC Switching: An Overview
6.1.1 What is OTC Switching?
6.1.2 Which Products Will Switch?
6.1.3 How Does OTC Switching Occur?
6.1.4 How Does OTC Switching Affect The OTC Pharma Market?
6.1.5 Opposition to OTC Switching
6.2 OTC Switching Activity, 2002-2014
6.2.1 OTC Switching: Downward Trend
6.2.2 The FDA NSURE Initiative: Reversing the Downward Trend in Rx-to-OTC Switches
6.3 Potential Candidates for OTC Switching 2015-2025
6.4 Cough, Cold and Allergy: OTC Switches
6.4.1 First-Generation Antihistamines
6.4.2 Allegra (fexofenadine)
6.4.3 Clarinex (desloratadine)
6.4.4 Flixotide/Flonase (fluticasone): Latest Nasal Corticosteroid Approval
6.4.5 Nasacort (triamcinolone): First in Class U.S. OTC Approval
6.5 Analgesics: OTC Switch Limitations
6.5.1 Triptans: The U.S. Will Remain Cautious
6.5.2 NSAIDs for Arthritis: Safety Concerns Incites Reverse-Switching
6.5.3 Other Analgesics
6.6 Gastrointestinals: OTC Switches
6.6.1 H2-Receptor Blockers
6.6.2 Proton pump inhibitors (PPIs)
6.6.2.1Omeprazole
6.6.2.2 Lansoprazole
6.6.2.3 Pantoprazole
6.6.2.4 Esomeprazole: 2014 U.S. FDA Approval for OTC Use
6.6.2.5 Rabeprazole
6.6.3 Anti-obesity drugs
6.7 Dermatologicals: OTC Switches
6.7.1 Antivirals for Oral Herpes Simplex
6.8 Anticholinergics for Incontinence: OTC Switches
6.9 Oral Contraceptives: An OTC Switch Can have Significant Economic Benefits
6.10 High Demand for OTC Cholesterol-Lowering Drugs
6.10.1 Lipitor (atorvastatin): Testing Times for Pfizer
6.10.2 Zocor Heart Pro (simvastatin) in the UK
6.10.3 OTC Statins: U.S. Historical Setbacks
6.11 Other Potential OTC Switch Categories
6.11.1 High blood pressure: Thiaside Diuretics
6.11.2 Erectile Dysfunction: Viagra (sildenafil), Cialis (tadalafil)
6.11.3 Osteoporosis: (Bisphosphonates) An Undertreated Disease, but a Very Unlikely OTC Switch
6.11.4 Insomnia: Silenor (doxepin)

7. Qualitative Analysis of the OTC Pharma Market, 2015-2025
7.1 SWOT Analysis of the OTC Pharmaceutical Market
7.2 Strengths
7.2.1 Healthcare Systems, Third Party Payers, and Manufacturers: All have Incentives to Push for OTC Drug Consumption
7.2.1.1 Manufacturers can Reap OTC Sales Benefits
7.2.1.2 Third Party Payers: Reducing the Cost Burden
7.2.1.3 Healthcare Systems: Pushing the Cost to the Consumer
7.2.2 Many Pharma Companies Have a Strong Potential OTC Portfolio
7.2.3 Regulators Are Encouraging OTC Approvals
7.2.4 Effective Distribution Networks Due to Expansion of Retail Pharmacy and Alternative Distributors
7.2.5 Deterring the Consumption of Counterfeit Drugs
7.2.6 Cultural Changes Will Support Self-Medication With OTC Medicines
7.3 Weaknesses
7.3.1 Pharma Companies Remain Focused on Prescription Drugs
7.3.2 Manufacturing Problems Affects Sales and Reputation of OTC Drugs
7.3.3 OTC Products are Vulnerable to Price Controls by Governments
7.3.4 Downward Cost Pressures of OTC Drugs
7.4 Opportunities
7.4.1 Demographic and Economic Changes Will Create Growth Opportunities
7.4.2 New OTC Switch Categories
7.4.3 Strong Growth in Emerging Markets
7.4.4 New Healthcare Technologies May enable OTC Approvals
7.4.5 Opportunities to Drive Sales Via Social Media and Online Marketing
7.4.6 Self Medication can Reduce the Under Treatment of Disease
7.5 Threats
7.5.1 Competition from Private-Label Brands Will Reduce Profitability
7.5.2 Regulatory Concerns Over Safety and Misuse may Lead to Withdrawal of Products
7.5.3 Resistance to OTC Switching from Some Groups in Certain Countries
7.6 Porter’s Five Forces Analysis of the OTC Pharmaceutical Market
7.6.1 Rivalry Among Competitors [High]
7.6.2 Threat of New Entrants [Medium]
7.6.3 Power of Suppliers [Low]
7.6.4 Power of Buyers [Medium]
7.6.5 Threats of Substitutes [Medium]

8. Expert Opinions
8.1 Interview with Professor Joshua P. Cohen, PhD, Tufts Center for the Study of Drug
Development, Boston, Massachusetts, USA
8.1.1 Major OTC Consolidation
8.1.2 The Creation of a Behind the Counter Class in the U.S.
8.1.3 Future Rx-OTC Switches
8.1.4 Prospects for OTC Statins in the U.S.
8.1.5 The NSURE (Non-Prescription Safe Use Regulatory Expansion) Initiative
8.1.6 The Rate of OTC Switching
8.1.7 American Consumers Perception of OTC Drugs
8.1.8 The Under-treatment of Disease in America
8.1.9 Health Impacts of Potential Rx-OTC Switching
8.1.10 The U.S OTC Regulatory Process- Too Stringent?
8.2 Interview with Mr David Spangler, Senior Vice President, US Consumer Health Products
Association, Washington DC, USA
8.2.1 Prospects for a Behind-the-Counter Class of OTC Drugs in the US
8.2.2 Obama’s Affordable Care Act and the OTC Industry
8.2.3 Major Restraints on Pharma OTC Growth
8.2.4 Shifting Formal Healthcare to the Retail

9. Conclusions
9.1 The World OTC Pharma Market in 2013-2014
9.1.1 The Leading OTC Product Categories
9.1.2 Leading OTC Pharma Brands, 2013
9.1.3 Leading OTC Manufacturers
9.1.4 Leading National Markets: Emerging Market Represent a Large Proportion
9.1.5 The Global OTC Market Growth Factors
9.1.6 Potential OTC Switching, 2015-2025
9.1.7 Emerging OTC Markets
9.2 Concluding Remarks

List of Tables
Table 1.1 The EU5 OTC Pharma Market Forecast: Sales ($bn), AGR (%), CAGR (%) by Region, 2013-2025
Table 2.1 OTC Internal Analgesic Active Ingredients, 2014
Table 2.2 OTC External Analgesic Active Ingredients, 2014
Table 2.3 OTC Cough, Cold and Allergy Active Ingredients, 2014
Table 2.4 OTC Antifungal Active Ingredients, 2014
Table 2.5 OTC Indigestion and Heartburn Active Ingredients, 2014
Table 2.6 OTC Anti-Diarrhoea Active Ingredients, 2014
Table 2.7 OTC Laxative Active Ingredients, 2014
Table 2.8 OTC Dry Eye Syndrome Active Ingredients, 2014
Table 2.9 OTC Bacterial Conjunctivitis Active Ingredients, 2014
Table 2.10 OTC Ocular Allergy Active Ingredients, 2014
Table 2.11 OTC Smoking Cessation Aid Active Ingredients, 2014
Table 3.1 The World OTC Pharmaceutical Market: Revenues ($bn) and Market Shares (%) by Product Category, 2013-2014
Table3.2 Top 10 OTC Pharmaceutical Products: Revenues ($m), 2013
Table 3.3 Top 10 OTC Pharmaceutical Manufacturers; Revenues ($bn) and Market Shares (%), 2013
Table 3.4 The World OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2013-2025
Table 3.5 The World OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%) by Product Category, 2013-2025
Table 3.6 The World OTC Pharma Market Forecast: CAGR (%) by Product Category, 2013-2019, 2019-2025 and 2013-2025
Table 3.7 Market Shares (%) of the OTC Pharmaceutical Market by Category, 2013, 2019 and 2025
Table 3.8 The Cough, Cold and Allergy OTC Pharma Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2025
Table 3.9 The Analgesics OTC Pharma Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2025
Table 3.10 The Gastrointestinals OTC Pharma Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2025
Table 3.11 The Dermatological OTC Pharma Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2025
Table 3.12 The Eye Care OTC Pharma Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2025
Table 3.13 The Smoking Cessation Aids OTC Pharma Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2025
Table 3.14 The Other Products OTC Pharma Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2025
Table 4.1 The World OTC Pharmaceutical Market: Revenues ($bn) and Market Shares (%) by Region, 2013
Table 4.2 The World OTC Pharmaceutical Market Forecast: Revenues ($bn), AGR (%), CAGR (%) by Region, 2013-2025
Table 4.3 Regional OTC Pharmaceutical Market Forecast: CAGR (%), 2013-2019, 2019-2025 and 2013-2025
Table 4.4 Market Shares (%) of the Leading Regional OTC Pharmaceutical Markets, 2013, 2019 and 2025
Table 4.5 The US OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2013-2025
Table 4.6 Top 10 US OTC Pharma Companies: OTC Revenues ($m), Net Revenues ($m), 2013
Table 4.7 The Japanese OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2013-2025
Table 4.8 Top 10 Japanese OTC Pharma Companies: OTC Revenues ($m), Net Revenues ($m), 2013
Table 4.9 The EU5 Market: Revenue ($bn), Market Share (%) by Region, 2013-2014
Table 4.10 The EU5 OTC Pharma Market: Market Shares (%) by National Market, 2013, 2019, 2025
Table 4.11 The EU5 OTC Pharma Market Forecast by Country: Revenues ($bn), AGR (%), CAGR (%), 2013-2025
Table 4.12 Top 5 EU5 OTC Pharma Companies: OTC Revenues ($m), Net Revenues ($m), 2013
Table 4.13 The German OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2013-2025
Table 4.14 The UK OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2013-2025
Table 4.15 The French OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2013-2025
Table 4.16 The Italian OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2013-2025
Table 4.17 The Spanish OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2013-2025
Table 4.18 The Chinese OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2013-2025
Table 4.19 Top 10 Chinese OTC Pharma Companies: OTC Revenues ($m), Net Revenues ($m), 2013
Table 4.20 The Brazilian OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2013-2025
Table 4.21 Top 5 Brazilian OTC Pharma Companies: OTC Revenues ($m), Net Revenues ($m), 2013
Table 4.22 The Russian OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2013-2025
Table 4.23 Top 5 Russian OTC Pharma Companies: OTC Revenues ($m), Net Revenues, 2013
Table 4.24 The Indian OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2013-2025
Table 4.25 Top 10 Indian OTC Pharma Companies: OTC Revenues ($m), Net Revenues ($m), 2013
Table 4.26 The Mexican OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2013-2025
Table 4.27 The Turkish OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2013-2025
Table 4.28 The Indonesian OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2013-2025
Table 4.29 The Rest of the World OTC Pharma Market Forecast: Revenues ($bn), AGR (%),
CAGR (%), 2013-2025
Table5.1 Top 10 OTC Pharmaceutical Manufacturers: Revenues ($bn) and Market Shares (%), 2013
Table5.2Projected Top 10 OTC Pharmaceutical Manufacturers: Revenues ($bn) and Market
Shares (%), 2015
Table5.3 GSK: Overview, 2013
Table 5.4 GSK OTC Brands, 2014
Table 5.5 GSK Consumer Healthcare: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2013-2025
Table 5.6 Panadol OTC Products, 2014
Table 5.7 Panadol: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2013-2025
Table 5.8 Nicorette OTC Products, 2014
Table 5.9 Novartis Overview, 2013
Table 5.10 Novartis OTC Brands, 2014
Table 5.11Novartis: Voltaren OTC Sales Forecast ($m), AGR (%), CAGR (%), 2013-2025
Table 5.12 Bayer: Overview, 2013
Table 5.13 Bayer OTC Brands, 2014
Table 5.14 Bayer: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2013-2025
Table 5.15 Bayer Aspirin: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2013-2025
Table 5.16 Merck: Overview, 2013
Table 5.17 Merck OTC Brands, 2014
Table 5.18 Claritin OTC: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2013-2025
Table 5.19 Johnson & Johnson Overview, 2013
Table 5.20 Johnson & Johnson OTC Brands, 2014
Table 5.21 Johnson & Johnson: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2013-2025
Table 5.22 Tylenol OTC Products, 2014
Table 5.23 Tylenol Sales Forecast ($m), AGR (%), CAGR (%), 2013-2025
Table 5.24 Nicorette OTC Products, 2014
Table 5.25 Perrigo: Overview, 2013
Table 5.26 Perrigo: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2013-2025
Table 5.27 Pfizer: Overview, 2013
Table 5.28 Pfizer OTC Brands, 2014
Table 5.29 Pfizer: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2013-2025
Table 5.30 Advil OTC Brands, 2014
Table 5.31 Advil: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2013-2025
Table 5.32 Procter& Gamble: Overview, 2013
Table 5.33 Reckitt Benckiser: Overview, 2013
Table 5.34 Reckitt Benckiser: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2013-2025
Table 5.35 Sanofi: Overview, 2013
Table 5.36 Sanofi OTC Brands, 2014
Table 5.37 Sanofi: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2013-2025
Table 5.38 Boehringer Ingelheim: Overview, 2013
Table 5.39 Boehringer Ingelheim OTC Brands, 2014
Table 5.40 Boehringer Ingelheim: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2013-2025
Table 6.1 US OTC Switches by Manufacturer, 2002-July 2014
Table 6.2 Potential Cough, Cold and Allergy OTC Switches By Active Ingredient, 2015-2015
Table 6.3 Potential Analgesics OTC Switches by Active Ingredient, 2015-2025
Table 6.4 Potential Gastrointestinals OTC Switches By Active Ingredient, 2015-2025
Table 6.5 Potential Dermatologicals OTC Switches By Active Ingredient, 2015-2025
Table 7.1 SWOT Analysis of the OTC Pharmaceutical Market, 2014

List of Figures
Figure 1.1 The World OTC Pharmaceuticals Market: Market Share (%) by Leading Company, 2013
Figure 1.2 OTC Pharmaceuticals: Overview of Submarkets
Figure 2.1 The OTC Pharmaceutical Supply Chain, 2014
Figure 3.1 The World OTC Pharmaceutical Market: Market Share (%) of the World
Pharmaceutical Market , 2013
Figure 3.2 The World OTC Pharmaceutical Market: Market Shares (%) by Product Category, 2013
Figure 3.3 The World OTC Pharma Market Forecast: Revenues ($bn), AGR (%) 2013-2025
Figure 3.4 The World OTC Pharmaceutical Market: CAGR (%) by Product Category, 2013-2019
Figure 3.5 The World OTC Pharmaceutical Market: CAGR (%) by Product Category, 2019-2025
Figure 3.6 The World OTC Pharmaceutical Market: CAGR (%) by Product Category, 2013-2025
Figure 3.7 The World OTC Pharmaceutical Market: Market Shares (%) by Product Category, 2019
Figure 3.8 The World OTC Pharmaceutical Market: Market Shares (%) by Product Category,
2025
Figure 3.9 The Cough, Cold and Allergy OTC Pharma Market Forecast: Revenues ($bn), AGR (%), 2013-2025
Figure 3.10 The Analgesics OTC Pharma Market Forecast: Revenues ($bn), AGR (%), 2013-2025
Figure 3.11The Gastrointestinals OTC Pharma Market Forecast: Revenues ($bn), AGR (%), 2013-2025
Figure 3.12 The Dermatological OTC Pharma Market Forecast: Revenues ($bn), AGR (%), 2013-2025
Figure 3.13 The Eye Care OTC Pharma Market Forecast: Revenues ($bn), AGR (%), 2013-2025
Figure 3.14 The Smoking Cessation Aids OTC Pharma Market Forecast: Revenues ($bn), AGR (%), 2013-2025
Figure 3.15 The Other Products OTC Pharma Market Forecast: Revenues ($bn), AGR (%), 2013-2025
Figure 4.1 The World OTC Pharmaceutical Market: Revenues ($bn) by Region, 2013
Figure 4.2 The World OTC Pharmaceutical Market: Market Shares (%) by Region,2013
Figure 4.3 Regional OTC Pharmaceutical Market Forecast: CAGR (%), 2013-2019
Figure 4.4 Regional OTC Pharmaceutical Market Forecast: CAGR (%), 2019-2025
Figure 4.5 Regional OTC Pharmaceutical Market Forecast: CAGR (%), 2013-2025
Figure 4.6 The World OTC Pharmaceutical Market: Market Shares (%) by Region, 2019
Figure 4.7 The World OTC Pharmaceutical Market: Market Shares (%) by Region, 2025
Figure 4.8 The US OTC Pharma Market Forecast: Revenues ($bn), AGR (%), 2013-2025
Figure 4.9 The Japanese OTC Pharma Market Forecast: Revenues ($bn), AGR (%), 2013-2025
Figure 4.10 The EU5 OTC Pharmaceutical Market : Market Shares (%) by National Market, 2013
Figure 4.11 The EU5 OTC Pharmaceutical Market : Market Shares (%) by National Market, 2019
Figure 4.12 The EU5 OTC Pharmaceutical Market : Market Shares (%) by National Market, 2025
Figure 4.13 The EU5 OTC Pharma Market Forecast: Revenues ($bn), AGR (%), 2013-2025
Figure 4.14 The German OTC Pharma Market Forecast: Revenues ($bn), AGR (%), 2013-2025
Figure 4.15 The UK OTC Pharma Market Forecast: Revenues ($bn), AGR (%), 2013-2025
Figure 4.16 The French OTC Pharma Market Forecast: Revenues ($bn), AGR (%), 2013-2025
Figure 4.17 The Italian OTC Pharma Market Forecast: Revenues ($bn), AGR (%), 2013-2025
Figure 4.18 The Spanish OTC Pharma Market Forecast: Revenues ($bn), AGR (%), 2013-2025
Figure 4.19 The Chinese OTC Pharma Market Forecast: Revenues ($bn), AGR (%), 2013-2025
Figure 4.20 The Brazilian OTC Pharma Market Forecast: Revenues ($bn), AGR (%), 2013-2025
Figure 4.21 The Russian OTC Pharma Market Forecast: Revenues ($bn), AGR (%), 2013-2025
Figure 4.22 The Indian OTC Pharma Market Forecast: Revenues ($bn), AGR (%), 2013-2025
Figure 4.23 The Mexican OTC Pharma Market Forecast: Revenues ($bn), AGR (%), 2013-2025
Figure 4.24 The Turkish OTC Pharma Market Forecast: Revenues ($bn), AGR (%), 2013-2025
Figure 4.25 The Indonesian OTC Pharma Market Forecast: Revenues ($bn), AGR (%), 2013-2025
Figure 4.26 The Rest of the World OTC Pharma Market Forecast: Revenues ($bn), AGR (%), 2013-2025
Figure 5.1 Leading OTC Pharmaceutical Manufacturers by Market Share (%), 2013
Figure 5.2 Projected Leading OTC Pharmaceutical Manufacturers by Market Share (%), 2015
Figure 5.3 GSK Consumer Healthcare: OTC Sales Forecast ($m), AGR (%), 2013-2025
Figure 5.4 Panadol: OTC Sales Forecast ($m), AGR (%), 2013-2025
Figure 5.5 Novartis: Voltaren OTC Sales Forecast ($m), AGR (%), 2013-2025
Figure 5.6 Bayer: OTC Sales Forecast ($m), AGR (%), 2013-2025
Figure 5.7 Bayer Aspirin: OTC Sales Forecast ($m), AGR (%), 2013-2025
Figure 5.8 Claritin OTC: OTC Sales Forecast ($m), AGR (%), 2013-2025
Figure 5.9 Johnson & Johnson: OTC Sales Forecast ($m), AGR (%),2013-2025
Figure 5.10 Tylenol Sales Forecast ($m), AGR (%), 2013-2025
Figure 5.11 Perrigo: OTC Sales Forecast ($m), AGR (%), 2013-2025
Figure 5.12 Pfizer: OTC Sales Forecast ($m), AGR (%), 2013-2025
Figure 5.13 Advil: OTC Sales Forecast ($m), AGR (%), 2013-2025
Figure 5.14 Reckitt Benckiser: OTC Sales Forecast ($m), AGR (%), 2013-2025
Figure 5.15 Sanofi: OTC Sales Forecast ($m), AGR (%), 2013-2025
Figure 5.16 Boehringer Ingelheim: OTC Sales Forecast ($m), AGR (%), 2013-2025
Figure 6.1 Number of FDA-Approved OTC Switches, By Year, 1976-2014
Figure 6.2 Number of FDA-Approved OTC Switches, By 5-Year Periods, 1976-2014
Figure 7.1 Porter’s Five Analysis of the OTC Pharmaceutical Market , 2014
Figure 9.1 The World OTC Pharmaceutical Market: Revenues ($bn) by Region, 2013
Figure 9.2 The World OTC Pharmaceutical Forecast: Sales ($bn), 2013-2025
Figure 9.3 World Population Forecast: Size ($bn), 2015-2025
Figure 9.4 World 65+ Population Forecast: Size (m), 2015-2025

【レポートのキーワード】

OTC医薬品(一般用医薬品)、市場規模、販売、製薬

★調査レポート[OTC医薬品(一般用医薬品)の世界市場] ( World OTC Pharmaceuticals Market Forecast 2015-2025 : Prospects For Leading Companies / VGAIN4121911) 販売に関する免責事項
[OTC医薬品(一般用医薬品)の世界市場] ( World OTC Pharmaceuticals Market Forecast 2015-2025 : Prospects For Leading Companies / VGAIN4121911) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆